

Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	8 September 2020
Date of last disclosure:	21 August 2019
Director or senior manager giving disclosure	
Full name(s):	Gordon Neil MacLeod
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Executive
Summary of acquisition or disposal of relevant interest (excluding specified derivative	res)
(1)	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
	Beneficial owner subject to the terms of
Nature of the affected relevant interest(s):	the Ryman Healthcare Limited Employee Share Scheme
For that relevant interest-	
Number held in class before acquisition or disposal:	273,418
Number held in class after acquisition or disposal:	255,237
Teamber field in class area acquisition or disposal	David William Kerr & Warren James Bell
Current registered holder(s):	as custodian for the Ryman Healthcare Limited Employee Share Scheme (held as bare trustees)
Registered holder(s) once transfers are registered:	N/A
Tregistered Holder(s) office transfers are regionales.	
(2)	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
For that relevant interest-	
Number held in class before acquisition or disposal:	387,545
Number held in class after acquisition or disposal:	423,847
Current registered holder(s):	Gordon Neil MacLeod
Registered holder(s) once transfers are registered:	N/A
Registered holder(s) office transfers are registered.	IWA
Summary of acquisition or disposal of specified derivatives relevant interest (if applied	cable)
Type of affected derivative:	
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable	
under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	Three
Details of transactions requiring disclosure-	THICO
1)	4
Date of transaction:	1 September 2020
Nature of transaction:	Transfer of legal title to 107,106 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian (as bare trustees) for the Ryman Healthcare Limited Employee Share Scheme to Gordon Neil MacLeod, in accordance with such terms
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	N/A
Number of financial products to which the transaction related:	107,106
	.67,185
2)	
Date of transaction:	1 September 2020
	Acquisition of beneficial interest in 88,925 ordinary shares subject to the terms of the Ryman Healthcare Limited
Nature of transaction:	Employee Share Scheme
lame of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a leash value, describe the consideration:	
	\$1,200,000 (being \$13.468 per share)
Number of financial products to which the transaction related:	88,925
3)	
Date of transaction:	1 September 2020
lature of transaction:	On market sale
lame of any other party or parties to the transaction (if known):	N/A
he consideration, expressed in New Zealand dollars, paid or received for the acquisition r disposal. If the consideration was not in cash and cannot be readily by converted into a	
ash value, describe the consideration:	\$953,588 (being \$13.468 per share)
lumber of financial products to which the transaction related:	70,804
f the Issuer has a financial products trading policy that prohibits directors or senior nanagers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period: Whether prior written clearance was provided to allow the acquisition or disposal to	No
proceed during the closed period: Date of the prior written clearance (if any):	
summary of other relevant interests after acquisition or disposal:	
class of quoted financial products:	N/A
ature of relevant interest.	
lature of relevant interest: For that relevant interest,- lumber held in class:	

For a derivative relevant interest,-		
Type of derivative:	J	
Details of derivative,-	1	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	2	œ
A statement as to whether the derivative is cash settled or physically settled:		
Maturity date of the derivative (if any):		
Expiry date of the derivative (if any):		
The price's specified terms (if any):		
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:		
For that derivative relevant interest,-		
Parties to the derivative:		
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:		
Certification	-0	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.		
Signature of director or officer:		
Date of signature:	8 September 2020	
or		
Signature of person authorised to sign on behalf of director or officer.		
Date of signature:		
Name and title of authorised person:		

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	8 September 2020
Date of last disclosure:	21 August 2019
Director or senior manager giving disclosure	
Full name(s):	David Bennett
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Financial Officer
Commence of acquisition and demonstrate interest (evaluating appointed designating	os)
Summary of acquisition or disposal of relevant interest (excluding specified derivative	63)
(1)	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Note that the effect of a long of the specific to	Beneficial owner subject to the terms of the Ryman Healthcare Limited Employee
Nature of the affected relevant interest(s):	Share Scheme
For that relevant interest-	
Number held in class before acquisition or disposal:	96.893
Number held in class after acquisition or disposal:	119,934
Current registered holder(s):	David William Kerr & Warren James Bell as custodian for the Ryman Healthcare Limited Employee Share Scheme (held as bare trustees)
Registered holder(s) once transfers are registered:	N/A
(2)	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
For that relevant interest-	
Number held in class before acquisition or disposal:	32,724
Number held in class after acquisition or disposal:	32,724
Current registered holder(s):	David Bennett
Registered holder(s) once transfers are registered:	N/A
Summary of acquisition or disposal of specified derivatives relevant interest (if applie	cable)
Type of affected derivative:	
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial	
products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	

	3
f the director or senior manager is not a party to the derivative, the nature of the relevant	
nterest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	Three
Details of transactions requiring disclosure-	
1)	
Date of transaction:	1 September 2020
Nature of transaction:	Transfer of legal title to 21,421 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian (as bare trustees) for the Ryman Healthcare Limited Employee Share Scheme to David Bennett, in accordance with such terms
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition	
or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	N/A
Number of financial products to which the transaction related:	21,421
tamber of infantial products to which the transaction related.	21,421
2)	
Date of transaction:	1 September 2020
Nature of transaction:	Acquisition of beneficial interest in 44,462 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	N/A \$600,000 (being \$13.468 per share)
Sumber of financial products to which the transaction related:	44,462
3)	
ate of transaction:	1 September 2020
ature of transaction:	On market sale
ame of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition r disposal. If the consideration was not in cash and cannot be readily by converted into a ash value, describe the consideration:	\$288,498 (being \$13.468 per share)
lumber of financial products to which the transaction related:	21,421
f the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) nclude the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	No
hether prior written clearance was provided to allow the acquisition or disposal to	
roceed during the closed period: late of the prior written clearance (if any):	
ummary of other relevant interests after acquisition or disposal:	
lass of quoted financial products:	N/A
lature of relevant interest:	
or that relevant interest -	
For that relevant interest,-	

For a derivative relevant interest,-	
Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification	70.70
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	1/MS
Date of signature:	8 September 2020
or /	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	

Name and title of authorised person:

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	7
Name of listed issuer:	
Date this disclosure made:	Ryman Healthcare Limited
Date of last disclosure:	8 September 2020
The state of the s	21 August 2019
Director or senior manager giving disclosure	
Full name(s):	
Name of listed issuer:	Tom Brownrigg
Name of related body corporate (if applicable):	Ryman Healthcare Limited
Position held in listed issuer:	
- Soliton field in listed issuer.	Chief Construction Officer
o militario de la companya della companya della companya de la companya della com	The state of the s
Summary of acquisition or disposal of relevant interest (excluding specified derivati	100
	ves)
(1) Class of affected quoted financial products:	-
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Beneficial owner subject to the terms of
relation of the directed relevant interest(s).	the Ryman Healthcare Limited Employee
For that relevant interest-	Share Scheme
Number held in class before acquisition or disposal:	
Number held in class after acquisition or disposal:	125,998
	127,618
Current registered holder(s):	David William Kerr & Warren James Bell as custodian for the Ryman Healthcare
ourient registered floider(s).	Limited Employee Share Scheme (held
	as bare trustees)
Registered holder(s) once transfers are registered:	N/A
(0)	
(2)	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s): For that relevant interest-	Registered holder and beneficial owner
Number held in class before acquisition or disposal:	214,129
Number held in class after acquisition or disposal:	214,129
Current registered holder(s):	Tom Brownrigg
registered holder(s) once transfers are registered:	N/A
registered noticer(s) once transfers are registered:	N/A
Summary of acquisition or disposal of specified derivatives relevant interest (if applic	
Summary of acquisition or disposal of specified derivatives relevant interest (if application of affected derivative:	
Summary of acquisition or disposal of specified derivatives relevant interest (if applic Type of affected derivative: Class of underlying financial products:	
Summary of acquisition or disposal of specified derivatives relevant interest (if applic Type of affected derivative: Class of underlying financial products: Details of affected derivative-	
Summary of acquisition or disposal of specified derivatives relevant interest (if application of acquisition or disposal of specified derivatives relevant interest (if application of affected derivative) The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
Summary of acquisition or disposal of specified derivatives relevant interest (if applied for affected derivative: Class of underlying financial products: Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled:	
Summary of acquisition or disposal of specified derivatives relevant interest (if applied for affected derivative: Class of underlying financial products: Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any):	
Summary of acquisition or disposal of specified derivatives relevant interest (if applied for affected derivative: Class of underlying financial products: Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative(if any):	
Summary of acquisition or disposal of specified derivatives relevant interest (if applied for affected derivative: Class of underlying financial products: Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative(if any):	
Summary of acquisition or disposal of specified derivatives relevant interest (if applied Type of affected derivative: Class of underlying financial products: Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative(if any): The price specified in the terms of the derivative (if any): Any other details needed to understand how the amount of the consideration payable.	
Registered holder(s) once transfers are registered: Summary of acquisition or disposal of specified derivatives relevant interest (if applied for affected derivative: Class of underlying financial products: Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative(if any): The price specified in the terms of the derivative (if any): Any other details needed to understand how the amount of the consideration payable underlying financial products:	
Summary of acquisition or disposal of specified derivatives relevant interest (if applied applied of affected derivative: Class of underlying financial products: Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative(if any): The price specified in the terms of the derivative (if any): Any other details needed to understand how the amount of the consideration payable ander the derivative or the value of the derivative is affected by the value of the	

Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	Three
Details of transactions requiring disclosure-	lak terjapan akan aki mana atau ak
(1)	with an end of description with freezy Williams
Date of transaction:	1 September 2020
Nature of transaction:	Transfer of legal title to 42,842 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian (as bard trustees) for the Ryman Healthcare Limited Employee Share Scheme to Tom Brownrigg, in accordance with such terms
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a lash value, describe the consideration:	N/A
Number of financial products to which the transaction related:	
The second of th	42,842
2)	
Date of transaction:	1 September 2020
CA CONTRACTOR OF THE PARTY OF T	Acquisition of beneficial interest in
Nature of transaction:	44,462 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	N/A \$600,000 (being \$13.468 per share)
Number of financial products to which the transaction related:	44,462
	71,102
Marian and a second	
ate of transaction:	1 September 2020
ature of transaction:	On market sale
ame of any other party or parties to the transaction (if known):	N/A
he consideration, expressed in New Zealand dollars, paid or received for the acquisition r disposal. If the consideration was not in cash and cannot be readily by converted into a ash value, describe the consideration:	\$576,996 (being \$13.468 per share)
lumber of financial products to which the transaction related:	42,842
	42,042
the issuer has a financial products trading policy that prohibits directors or senior anagers from trading during any period without written clearance (a closed period) clude the following details—	
/hether relevant interests were acquired or disposed of during a closed period: /hether prior written clearance was provided to allow the acquisition or disposal to roceed during the closed period:	No
ate of the prior written clearance (if any):	
ummary of other relevant interests after acquisition or disposal:	
ass of quoted financial products:	N/A
ature of relevant interest:	I VITA
or that relevant interest,-	
umber held in class:	

Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature: 8/9/20	8 September 2020
or //	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	8 September 2020
Date of last disclosure:	28 January 2020
	,
Director or senior manager giving disclosure	17
Full name(s):	Nicole Forster
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief People and Technology Officer
, 00101110121111111111111111111111111111	officer copic and realificingly officer
Summary of acquisition or disposal of relevant interest (excluding specified derivative	es)
(4)	
(1) Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Olass of affected quoted finalional products.	Beneficial owner subject to the terms of
Nature of the affected relevant interest(s):	the Ryman Healthcare Limited Employee
	Share Scheme
For that relevant interest-	
Number held in class before acquisition or disposal:	89,209
Number held in class after acquisition or disposal:	67,788
	David William Kerr & Warren James Bell
Current registered holder(s):	as custodian for the Ryman Healthcare
(-)	Limited Employee Share Scheme (held as bare trustees)
Registered holder(s) once transfers are registered:	
Registered flotoer(s) office transfers are registered.	N/A
(2)	
(2) Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
For that relevant interest-	
Number held in class before acquisition or disposal:	18,071
Number held in class after acquisition or disposal:	39,492
Current registered holder(s):	Nicole Forster
Registered holder(s) once transfers are registered:	N/A
registered holder(b) office trainered are registered.	1071
Summary of acquisition or disposal of specified derivatives relevant interest (if applic	able)
Type of affected derivative:	
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial	
products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable	
under the derivative or the value of the derivative is affected by the value of the	
underlying financial products:	
For that derivative,-	
Parties to the derivative:	

If the director or senior manager is not a party to the derivative, the nature of the relevant	
interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	72
Total number of transactions to which notice relates:	One
Details of transactions requiring disclosure-	
(1)	
Date of transaction:	1 September 2020
Nature of transaction:	Transfer of legal title to 21,421 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian (as bare trustees) for the Ryman Healthcare Limited Employee Share Scheme to Nicole Forster, in accordance with such terms
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition	
or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	N/A
	N/A
Number of financial products to which the transaction related:	21,421
(2)	
(2)	
Date of transaction: Nature of transaction:	N/A
Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the acquisition	
or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	
Number of financial products to which the transaction related:	
(3)	
Date of transaction:	N/A
Nature of transaction:	
Name of any other party or parties to the transaction (if known):	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	
Number of financial products to which the transaction related:	_ = =
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to	
proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	
n 5	
Nature of relevant interest:	
For that relevant interest,-	Ţ
Number held in class:	
Current registered holder(s):	
For a derivative relevant interest,-	
Type of derivative:	

Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	
Date of signature: 8/9/20	8 September 2020
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	8 September 2020
Date of last disclosure:	17 January 2020
Director or senior manager giving disclosure	
Full name(s): Name of listed issuer:	Jeremy Moore
	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Development Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivative	es)
(1)	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Beneficial owner subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
For that relevant interest-	
Number held in class before acquisition or disposal:	61,257
Number held in class after acquisition or disposal:	89,653
Current registered holder(s):	David William Kerr & Warren James Bell as custodian for the Ryman Healthcare Limited Employee Share Scheme (as bare trustees)
Registered holder(s) once transfers are registered:	N/A
(2)	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
For that relevant interest-	-
Number held in class before acquisition or disposal:	10,450
Number held in class after acquisition or disposal:	0
Current registered holder(s):	Jeremy Moore
Registered holder(s) once transfers are registered:	N/A
Summary of acquisition or disposal of specified derivatives relevant interest (if applic	able)
Type of affected derivative:	
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	
Parties to the derivative:	

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	Three
Details of transactions requiring disclosure-	
(1)	
Date of transaction:	1 September 2020
Nature of transaction:	Transfer of legal title to 16,066 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme, from David William Kerr & Warren James Bell as custodian for the Ryman Healthcare Limited Employee Share Scheme to Jeremy Moore, in accordance with such terms
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	N/A
Number of financial products to which the transaction related:	16,066
(2)	
Date of transaction:	1 September 2020
Nature of transaction:	Acquisition of beneficial interest in 44,462 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$600,000 (being \$13.468 per share)
Number of financial products to which the transaction related:	44,462
(3)	
Date of transaction:	1 September 2020
Nature of transaction:	On market sale
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$357,117 (being \$13.468 per share)
Number of financial products to which the transaction related:	26,516
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period: Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	No
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	N/A
Nature of relevant interest:	
For that relevant interest,-	
Number held in class:	
Current registered holder(s):	

For a derivative relevant interest,-

Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification	
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	. \.()
Signature of director or officer:	- Hac
Date of signature:	8 September 2020
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



Disclosure of Directors and Senior Managers Relevant Interests

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	8 September 2020
Date of last disclosure:	N/A
Director or senior manager giving disclosure	
Full name(s):	Cheyne Chalmers
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Chief Operations Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivativ	es)
(1)	a ii li way ii man
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM) Beneficial owner subject to the terms of
Nature of the affected relevant interest(s):	the Ryman Healthcare Limited Employee Share Scheme
For that relevant interest-	
Number held in class before acquisition or disposal:	o
Number held in class after acquisition or disposal:	40,757
Current registered holder(s):	David William Kerr & Warren James Bell as custodian for the Ryman Healthcare Limited Employee Share Scheme (as bare trustees)
Registered holder(s) once transfers are registered:	N/A
(2) Class of affected quoted financial products: Nature of the affected relevant interest(s): For that relevant interest-	Ordinary shares (NZX code: RYM) Registered holder and beneficial owner
Class of affected quoted financial products: Nature of the affected relevant interest(s):	
Class of affected quoted financial products: Nature of the affected relevant interest(s): For that relevant interest- Number held in class before acquisition or disposal:	Registered holder and beneficial owner
Class of affected quoted financial products: Nature of the affected relevant interest(s): For that relevant interest- Number held in class before acquisition or disposal: Number held in class after acquisition or disposal:	Registered holder and beneficial owner 0
Class of affected quoted financial products: Nature of the affected relevant interest(s): For that relevant interest- Number held in class before acquisition or disposal:	Registered holder and beneficial owner 0 1,474
Class of affected quoted financial products: Nature of the affected relevant interest(s): For that relevant interest- Number held in class before acquisition or disposal: Number held in class after acquisition or disposal: Current registered holder(s): Registered holder(s) once transfers are registered: Summary of acquisition or disposal of specified derivatives relevant interest (if applied)	Registered holder and beneficial owner 0 1,474 Cheyne Chalmers N/A
Class of affected quoted financial products: Nature of the affected relevant interest(s): For that relevant interest- Number held in class before acquisition or disposal: Number held in class after acquisition or disposal: Current registered holder(s): Registered holder(s) once transfers are registered: Summary of acquisition or disposal of specified derivatives relevant interest (if applied type of affected derivative:	Registered holder and beneficial owner 0 1,474 Cheyne Chalmers N/A
Class of affected quoted financial products: Nature of the affected relevant interest(s): For that relevant interest- Number held in class before acquisition or disposal: Number held in class after acquisition or disposal: Current registered holder(s): Registered holder(s) once transfers are registered: Summary of acquisition or disposal of specified derivatives relevant interest (if applied to the product of the pr	Registered holder and beneficial owner 0 1,474 Cheyne Chalmers N/A
Class of affected quoted financial products: Nature of the affected relevant interest(s): For that relevant interest- Number held in class before acquisition or disposal: Number held in class after acquisition or disposal: Current registered holder(s): Registered holder(s) once transfers are registered: Summary of acquisition or disposal of specified derivatives relevant interest (if applied type of affected derivative:	Registered holder and beneficial owner 0 1,474 Cheyne Chalmers N/A
Class of affected quoted financial products: Nature of the affected relevant interest(s): For that relevant interest- Number held in class before acquisition or disposal: Number held in class after acquisition or disposal: Current registered holder(s): Registered holder(s) once transfers are registered: Summary of acquisition or disposal of specified derivatives relevant interest (if applied to the derivative: Class of underlying financial products: Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	Registered holder and beneficial owner 0 1,474 Cheyne Chalmers N/A
Class of affected quoted financial products: Nature of the affected relevant interest(s): For that relevant interest- Number held in class before acquisition or disposal: Number held in class after acquisition or disposal: Current registered holder(s): Registered holder(s) once transfers are registered: Summary of acquisition or disposal of specified derivatives relevant interest (if applied to the product of the derivative): Class of underlying financial products: Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled:	Registered holder and beneficial owner 0 1,474 Cheyne Chalmers N/A
Class of affected quoted financial products: Nature of the affected relevant interest(s): For that relevant interest- Number held in class before acquisition or disposal: Number held in class after acquisition or disposal: Current registered holder(s): Registered holder(s) once transfers are registered: Summary of acquisition or disposal of specified derivatives relevant interest (if applied to the derivative): Class of underlying financial products: Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any):	Registered holder and beneficial owner 0 1,474 Cheyne Chalmers N/A
Class of affected quoted financial products: Nature of the affected relevant interest(s): For that relevant interest- Number held in class before acquisition or disposal: Number held in class after acquisition or disposal: Current registered holder(s): Registered holder(s) once transfers are registered: Summary of acquisition or disposal of specified derivatives relevant interest (if applied to the derivative): Class of underlying financial products: Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative(if any):	Registered holder and beneficial owner 0 1,474 Cheyne Chalmers N/A
Class of affected quoted financial products: Nature of the affected relevant interest(s): For that relevant interest- Number held in class before acquisition or disposal: Number held in class after acquisition or disposal: Current registered holder(s): Registered holder(s) once transfers are registered: Summary of acquisition or disposal of specified derivatives relevant interest (if applied to the derivative): Class of underlying financial products: Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any):	Registered holder and beneficial owner 0 1,474 Cheyne Chalmers N/A
Class of affected quoted financial products: Nature of the affected relevant interest(s): For that relevant interest- Number held in class before acquisition or disposal: Number held in class after acquisition or disposal: Current registered holder(s): Registered holder(s) once transfers are registered: Summary of acquisition or disposal of specified derivatives relevant interest (if applied to affected derivative: Class of underlying financial products: Details of affected derivative- The notional value of the derivative (if any) or the notional amount of underlying financial products (if any): A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative(if any): The price specified in the terms of the derivative (if any): Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the	Registered holder and beneficial owner 0 1,474 Cheyne Chalmers N/A

If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Details of transactions giving rise to acquisition or disposal	2
Total number of transactions to which notice relates:	Two
Details of transactions requiring disclosure- (1)	
Date of transaction:	1 September 2020
Nature of transaction:	Acquisition of beneficial interest in 1,474 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
Name of any other party or parties to the transaction (if known):	N/A
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$20,000 (being \$13.468 per share)
Number of financial products to which the transaction related:	1,474
(4)	
(2)	4.0
Date of transaction:	1 September 2020 Acquisition of beneficial interest in 40,757 ordinary shares subject to the terms of the Ryman Healthcare Limited
Nature of transaction:	Employee Share Scheme
Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$550,000 (being \$13.468 per share)
Number of financial products to which the transaction related:	40,757
(3)	
Date of transaction:	N/A
Nature of transaction:	1471
Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	
Number of financial products to which the transaction related:	
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed period:	No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:	
Date of the prior written clearance (if any):	
Summary of other relevant interests after acquisition or disposal:	
Class of quoted financial products:	N/A
Nature of relevant interest:	
For that relevant interest,-	
Number held in class:	
Current registered holder(s):	
For a derivative relevant interest,-	
Type of derivative:	
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	

A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.	
Signature of director or officer:	Cheyma
Date of signature:	8 September 2020
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	

- (a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or
- (b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.



To NZX Limited; and

Name of listed issuer:
Date this disclosure made:

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

Date of last disclosure:	N/A
L. 91	
Director or senior manager giving disclosure	1
Full name(s):	Mary-Anne Stone
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	
Position held in listed issuer:	Acting Chief Sales and Marketing Officer
Summary of acquisition or disposal of relevant interest (excluding specified derivation	ves)
(1)	
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Beneficial owner subject to the terms of the Ryman Healthcare Limited Employee Share Scheme
For that relevant interest-	
Number held in class before acquisition or disposal:	0
Number held in class after acquisition or disposal:	22,231
Current registered holder(s):	David William Kerr & Warren James Bell as custodian for the Ryman Healthcare Limited Employee Share Scheme (as bare trustees)
Registered holder(s) once transfers are registered:	N/A
(2)	4 /
Class of affected quoted financial products:	Ordinary shares (NZX code: RYM)
Nature of the affected relevant interest(s):	Registered holder and beneficial owner
For that relevant interest-	
Number held in class before acquisition or disposal:	
Number held in class after acquisition or disposal:	1,486
Current registered holder(s):	Mary-Anne Stone
Registered holder(s) once transfers are registered:	N/A
Summary of acquisition or disposal of specified derivatives relevant interest (if appl	licable)
Class of underlying financial products:	
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	
A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative(if any):	
The price specified in the terms of the derivative (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative,-	

Ryman Healthcare Limited 8 September 2020

Details of transactions giving rise to acquisition or disposal		
Total number of transactions to which notice relates:	Two	
Details of transactions requiring disclosure-	140	
(1)		
Date of transaction:	1 September 2020	
Nature of transaction:	Acquisition of beneficial interest in 1,486 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme	
Name of any other party or parties to the transaction (if known):	N/A	
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	\$20,000 (being \$13.360 per share)	
Number of financial products to which the transaction related:	1,486	
(2)		
Date of transaction:	1 September 2020	
Nature of transaction:	Acquisition of beneficial interest in 22,231 ordinary shares subject to the terms of the Ryman Healthcare Limited Employee Share Scheme	
Name of any other party or parties to the transaction (if known):		
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:	N/A \$300,000 (being \$13.468 per share)	
Number of financial products to which the transaction related:	22,231	
(3)		
Date of transaction:	N/A	
Nature of transaction:		
Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:		
Number of financial products to which the transaction related:		
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—		8
Whether relevant interests were acquired or disposed of during a closed period:	No	
Whether prior written clearance was provided to allow the acquisition or disposal to		12
proceed during the closed period: Date of the prior written clearance (if any):		/
Summary of other relevant interests after acquisition or disposal:		
Class of quoted financial products:	N/A	
Nature of relevant interest:		
or that relevant interest,-		
Number held in class:		
Current registered holder(s):		
or a derivative relevant interest,-		
Type of derivative:		
7 (2) (2) (2) (3) (3) (3) (3) (3)		

ε

A statement as to whether the derivative is cash settled or physically settled:	
Maturity date of the derivative (if any):	
Expiry date of the derivative (if any):	
The price's specified terms (if any):	
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	
For that derivative relevant interest,-	
Parties to the derivative:	
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	
Certification I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons	
for whom it is made.	
Signature of director or officer:	
Date of signature:	8 September 2020
or	
Signature of person authorised to sign on behalf of director or officer:	
Date of signature:	
Name and title of authorised person:	

Use this form to disclose all the acquisitions and disposals by a director or senior manager of a listed issuer, or of a related body corporate, or in specified derivatives. The disclosure must be made within—

(a) 20 working days after the first acquisition or disposal disclosed in this notice if the acquisitions or disposals are of a kind referred to in section 297(2)(a) of the Financial Markets Conduct Act 2013; or

(b) in any other case, 5 trading days after the first acquisition or disposal disclosed in this notice.